^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    MRN complex inhibitor

    Related drugs:
    9ms
    A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors (clinicaltrials.gov)
    P1/2, N=6, Terminated, Valerio Therapeutics | N=165 --> 6 | Trial completion date: Dec 2028 --> Jan 2025 | Recruiting --> Terminated | Trial primary completion date: Jan 2026 --> Jan 2025; Business decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    VIO-01
    almost2years
    A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors (clinicaltrials.gov)
    P1/2, N=165, Recruiting, Valerio Therapeutics
    New P1/2 trial
    |
    VIO-01